Company news
Perspective Therapeutics, Inc. (AMEX:CATX) news
Perspective Therapeutics, Inc. news releases on 6ix. Latest, Sep 14, 2026: Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement…
Press releases & updates
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
September 14, 2026
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
July 31, 2026
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
July 28, 2026
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
June 3, 2026
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
May 18, 2026
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
April 24, 2026
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
April 20, 2026
Perspective Therapeutics to Participate in Upcoming Investor Conferences
April 2, 2026
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
March 17, 2026
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
March 16, 2026
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
February 17, 2026
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
February 2, 2026
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
January 9, 2026
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
December 4, 2025
Perspective Therapeutics to Participate in Upcoming December Conferences
November 20, 2025
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
November 10, 2025
Perspective Therapeutics to Participate in Upcoming November Conferences
October 31, 2025
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
October 24, 2025
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
October 2, 2025
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
September 15, 2025
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer
September 4, 2025
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
September 3, 2025
Perspective Therapeutics to Participate in Upcoming September Conferences
August 26, 2025
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results
August 13, 2025
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
July 24, 2025
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
July 15, 2025
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
June 21, 2025
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
June 21, 2025
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
May 30, 2025
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
May 12, 2025
Perspective Therapeutics to Participate in Upcoming May Investor Conferences
May 1, 2025
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
April 29, 2025
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
April 23, 2025